Prostaglandin as an effective antirejection therapy in rat renal allograft recipients.
Because adenylate cyclase activators such as prostaglandin E1 elevate lymphocytic cyclic AMP and inhibit T cell proliferation and the effector function of cytotoxic T cells in vitro, we tested the efficacy of 15(S)-15-methyl prostaglandin E1, a prostaglandin derivative with a prolonged biologic half-life. Treatment with this agent resulted in a near complete protection of renal grafts from immunologic damage, despite withholding therapy until day 4 following transplantation.
D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D006084:Graft Rejection / Q000187:drug effects*; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D051381:Rats
D011459:Prostaglandins E, Synthetic; C025170:15(S)-15-methylprostaglandin E1; D000527:Alprostadil